TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01786174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilenya
Description: 0.5mg Gilenya orally by mouth once daily for approximately 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
Study: NCT01059136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
Study: NCT02347228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB318 capsule
Description: Oral qd, at least 30 minutes before breakfast
Study: NCT03540953

Intervention type: DRUG
Group type: OTHER
Intervention: Endoscopic injection of Mitomycin C
Description: administration included dilation of the stenotic segment with thermoplastic bougies, followed by the injection of 3mg of Mitomycin C, divided into 4 aliquots of 0.75mg, injected in the four quadrants, at the stenosis level.
Study: NCT02041741

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly tips
Description: Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Tips
Description: Participants in this condition receive daily a set of small tips aimed at increasing happiness
Study: NCT02837835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime
Description: 20 mg/kg of body weight followed by 60 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime
Description: 20 mg/kg over 30 min every 8 h
Study: NCT01048567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus acidophilus/rhamnosus
Description: 2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules three times daily for entire duration of antibiotic therapy.
Study: NCT03130543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice cereal
Description: Standard formula thickened with rice cereal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enfamil AR
Description: Enfamil AR formula
Study: NCT02523053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatectomy
Description: Surgical removal of all lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Surgical removal of all lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
Study: NCT04721093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation device
Description: In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
Study: NCT00273767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta
Description: 800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 60ml of NaCl IV slow
Study: NCT02732054

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]
Description: Different HBV vaccine regimen in each group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]
Description: Different HBV vaccine regimen in each group
Study: NCT03077360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Lifestyle changes to lose weight or become more fit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Lifestyle changes to lose weight or become more fit
Study: NCT03736161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A- Tofacitinib
Description: Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group B- Methotrexate
Description: Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
Study: NCT03010930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplementation of diet with MSG
Description: Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No supplementation of diet with MSG
Description: Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
Study: NCT02532153

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine Hydrochloride
Description: Single open-label infusions
Study: NCT02151422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
Study: NCT04179331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurotensin
Description: Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Isotonic saline will serve as a placebo.
Study: NCT04074785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150 mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150 mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
Study: NCT00124852

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: n-3 Fatty Acid Supplementation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: n-3 Fatty Acid Supplementation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: n-3 Fatty Acid Supplementation
Study: NCT01765192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast was supplied in tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast was supplied in tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast placebo
Description: Roflumilast placebo was supplied in tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast placebo
Description: Roflumilast placebo was supplied in tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast was supplied in tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast was supplied in tablets.
Study: NCT03794908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy A (Bright) via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy B (Dim) via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
Study: NCT01486771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen ® (pegaptanib sodium)
Description: Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen ® (pegaptanib sodium)
Description: Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen ® (pegaptanib sodium)
Description: Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection.
Study: NCT02582125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Study: NCT02797353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Neonatal and Child Health Interventions
Description: Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
Study: NCT03520933

Intervention type: DIAGNOSTIC_TEST
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.

Intervention type: DIAGNOSTIC_TEST
Intervention: niPGT-A
Description: Non-invasive preimplantation genetic test for embryo aneuploidy analyzing the spent culture media where the embryo is incubated up to the time of vitrification. This media contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo.
Study: NCT01364363

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic transplantation
Description: Allogeneic transplantation with matched unrelated donors

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic transplantation
Description: Allogeneic transplantation with matched unrelated donors

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic transplantation
Description: Allogeneic transplantation with matched unrelated donors

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic transplantation
Description: Allogeneic transplantation with matched unrelated donors

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic transplantation
Description: Allogeneic transplantation with matched unrelated donors

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic transplantation
Description: Allogeneic transplantation with matched unrelated donors

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic transplantation
Description: Allogeneic transplantation with matched unrelated donors
Study: NCT02366377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT01315223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung impedence-guided treatment
Description: One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
Study: NCT03459144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin and ranibizumab
Description: Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin and ranibizumab
Description: Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin and ranibizumab
Description: Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
Study: NCT02677012

Intervention type: PROCEDURE
Intervention: Autologous Fat Graft
Description: Undergo AFG using the RESOLVE TM technique

Intervention type: PROCEDURE
Intervention: Autologous Fat Graft
Description: Undergo AFG using the Cytori PureGraft TM technique

Intervention type: PROCEDURE
Intervention: Autologous Fat Graft
Description: Undergo AFG using the Coleman technique

Intervention type: PROCEDURE
Intervention: Reconstructive Surgery
Description: Undergo reconstructive surgery

Intervention type: PROCEDURE
Intervention: Reconstructive Surgery
Description: Undergo reconstructive surgery

Intervention type: PROCEDURE
Intervention: Reconstructive Surgery
Description: Undergo reconstructive surgery
Study: NCT00876694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 µg
Description: Indacaterol 300 µg once daily (od) via SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50 µg
Description: Salmeterol 50 µg twice daily (bid) via Diskus®
Study: NCT00442065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aorfix™ Stent Grafts (AAA endovascular procedure)
Description: Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
Study: NCT02839954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MUC1 CAR-pNK cells
Study: NCT00288509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety \& efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
Study: NCT01019512

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lymphedema management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymphedema management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymphedema management
Study: NCT00730171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
Study: NCT03516630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Tablet
Study: NCT02902289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg/5 mL oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOMENT 200 mg coated tablet
Study: NCT01875172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Description: Comparison of bupropion SR or placebo + smoking cessation counseling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation counseling
Study: NCT01834196

Intervention type: DEVICE
Group type: OTHER
Intervention: Swept-Source Optical Coherence Tomography
Description: Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
Study: NCT01708122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg in 1 mL intranasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Sodium Chloride 0.9% intranasal spray
Study: NCT01030679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: 0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 1mg
Description: 1 mg/tablet, orally, 1 tablet once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 2mg
Description: 2 mg/tablet, orally, 1 tablet once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, 1 tablet once daily for 8 weeks
Study: NCT04256603

Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin
Description: Timing of gabapentin initiation
Study: NCT00643864

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mirror training
Description: Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests.
Study: NCT03487237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ddimer testing
Description: Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
Study: NCT02282618

Intervention type: DEVICE
Intervention: Cardiac Sympathetic Blockade
Study: NCT03611829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care